A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

本研究旨在明确贝那利珠单抗（benralizumab）是否可降低接受标准治疗的中至极重度有症状慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease，COPD）患者的急性加重率。